ទំព័រដើម › មហារីកសួត › អ៊ីលីណូអ៊ី › Chicago
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកសួត នៅក្នុង Chicago, IL
ការសិក្សាចំនួន 41 សម្រាប់ មហារីកសួត កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Chicago (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
កំពុងជ្រើសរើសដំណាក់កាល 3
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- និង 1 ទៀត
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- និង 1 ទៀត
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of Illinois Hospital & Health Sciences System ( Site 0044), Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of Illinois Cancer Center, Chicago
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- Northwestern University, Chicago
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of Illinois Cancer Center, Chicago
- Center for Care and Discovery, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of Illinois Chicago, Chicago
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Rush University Medical Center, Chicago
- University of Illinois Chicago, Chicago
A Registry for People With Lung Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Rush University Medical Center (Data collection only), Chicago
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Research Site, Chicago
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Rush University Medical Center, Chicago
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of Chicago Comprehensive Cancer Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of Illinois Hospital and Health Sciences Systems, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- Northwestern University, Chicago
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
កំពុងជ្រើសរើសដំណាក់កាល 1
- Xencor Investigative Site, Chicago
- Xencor Investigative Site, Chicago
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
កំពុងជ្រើសរើស
- Northwestern University, Chicago
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of Chicago, Chicago
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Northwestern Memorial Hospital, Chicago
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Northwestern Memorial Hospital, Chicago
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of Illinois Cancer Center, Chicago
The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- University of Illinois at Chicago, Chicago
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of Chicago Medicine, Chicago
Lung Cancer Screening in High-risk Black Individuals
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- University of Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1
- The University of Chicago Comprehensive Cancer Center, Chicago
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Advocate Illinois Masonic Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, Chicago
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- University of Chicago, Chicago
Olaparib in Patients With HRD Malignant Mesothelioma
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of Chicago Medical Center, Chicago
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Thoracic Surgery, Canning Thoracic Institute (Northwestern Memorial Hospital), Chicago
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Northwestern University, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- Northwestern University, Chicago
ការសាកល្បងសម្រាប់ មហារីកសួត នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 78
- Boston, MAការសិក្សា 62
- New York City, NYការសិក្សា 60
- Los Angeles, CAការសិក្សា 45
- Washington, DCការសិក្សា 41
- Arlington, VAការសិក្សា 41
- Nashville, TNការសិក្សា 40
- Baltimore, MDការសិក្សា 40
- St. Louis, MOការសិក្សា 39
- Columbus, OHការសិក្សា 37
- Philadelphia, PAការសិក្សា 36
- Seattle, WAការសិក្សា 33
ការសិក្សាផ្សេងទៀតនៅក្នុង Chicago
- Non-Small Cell Lung Cancerការសិក្សា 61
- មហារីកទ្រូងការសិក្សា 58
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 51
- មហារីកដែលរីករាលដាលការសិក្សា 45
- មហារីកតូចការសិក្សា 45
- ជំងឺធាត់ការសិក្សា 41
- មហារីកស៊ុតការសិក្សា 36
- ជំងឺគ្រុនចាញ់ការសិក្សា 34
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 33
- បេះដូងខ្សោយការសិក្សា 31
- ទម្ងន់លើសការសិក្សា 28
- មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅកការសិក្សា 26
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 5 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។